{"filings":[{"id":1140758,"accession_number":"0001104659-26-075849","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2026-06-18T21:14:49+00:00","items":["5.02","9.01"],"status":"ready","headline":"Petros Pharmaceuticals CFO Arnold departs; Robert Weinstein appointed as CAO/PFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mitchell Arnold mutually separated as VP Finance, Principal Financial & Accounting Officer, effective June 18, 2026.","Robert Weinstein appointed as Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer, effective immediately.","Separation includes $38,500 severance (2 months salary), accelerated vesting of 3,000 unvested shares, and 2 months COBRA premium subsidy.","Weinstein brings 30+ years experience; most recently CFO of TAO Synergies (formerly Synaptogenix) since 2013."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":890361,"accession_number":"0001104659-26-071027","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2026-06-05T21:00:31+00:00","items":["5.02"],"status":"ready","headline":"Petros Pharmaceuticals grants 7M restricted shares to Chairman, two directors, and President","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate 7,000,000 restricted shares granted to Joshua Silverman (Chairman), Bruce Bernstein, Fady Boctor, and Wayne Walker.","Silverman receives 4,375,000 shares; Bernstein 1,875,000; Boctor and Walker 375,000 each.","50% vested immediately on June 5, 2026; remaining 50% vests on six-month anniversary.","Issued outside the Amended and Restated 2020 Omnibus Incentive Compensation Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108963,"accession_number":"0001104659-26-000236","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Petros Pharmaceuticals grants 7.25M RSUs to executives and directors; 50% vested immediately","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Joshua Silverman (Chairman) receives 4,375,000 RSUs; Bruce Bernstein 1,875,000; Fady Boctor 500,000; Wayne Walker 500,000.","50% of each RSU grant vested on Jan 2, 2026; remaining 50% vests at six-month anniversary subject to continued service.","Grants issued outside the company's 2020 Omnibus Incentive Compensation Plan.","Total RSUs represent approximately 14% of current outstanding shares (est.) based on prior filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125414,"accession_number":"0001104659-25-108552","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq notifies Petros Pharmaceuticals of common stock delisting effective Nov 7, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Petros on Nov 3, 2025, of intention to delist common stock on Nov 7, 2025.","Stock suspended from Nasdaq Capital Market on May 22, 2025; trading on OTCID since July 1, 2025.","Nasdaq to file Form 25 to deregister stock under Section 12(b); delisting effective 10 days later.","Common stock continues trading on OTCID symbol PTPI without disruption; SEC reporting obligations remain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142149,"accession_number":"0001104659-25-087887","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Petros Pharmaceuticals dismisses CBIZ CPAs, appoints HTL International as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved dismissal of CBIZ CPAs as auditor effective Aug 29, 2025.","CBIZ CPAs had been engaged on April 5, 2025 after acquiring Marcum's attest business.","No disagreements with CBIZ CPAs; only reportable event was previously disclosed material weakness in internal controls.","Engaged HTL International as new independent auditor for fiscal year ending Dec 31, 2025, effective Aug 29.","No prior consultations with HTL regarding accounting or auditing matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160137,"accession_number":"0001104659-25-061230","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Petros Pharmaceuticals assigns subsidiary assets (Metuchen, Timm, Pos-T-Vac) to creditor trust","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective June 16, 2025, Petros assigned all assets of subsidiaries Metuchen, Timm Medical, and Pos-T-Vac to a third-party fiduciary for benefit of creditors.","The Vivus License Agreement for Stendra® was terminated March 31, 2025; Petros lost all rights to Stendra in the Licensed Territory.","Pro forma balance sheet shows stockholders' equity of $8.0M as of March 31, 2025, reflecting deconsolidation, warrant exercises, and redemptions.","Subsidiaries' operations classified as discontinued; deconsolidation from Petros' balance sheet expected in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160136,"accession_number":"0001104659-25-051336","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Petros Pharma receives Nasdaq delisting notice; trading to move to OTC Markets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Delisting due to failing minimum equity, bid price ($1.00), and public interest concerns from Feb 2025 offering.","Trading suspended on Nasdaq at open May 22, 2025; expected to trade on OTC Markets under PTPI.","Company has 15 days to appeal to Nasdaq Listing Council; appeal stays Form 25 but not suspension.","No assurance that Listing Council will grant continued listing on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160135,"accession_number":"0001104659-25-044240","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["3.01","3.03","5.03","9.01"],"status":"ready","headline":"Petros gets additional Nasdaq delisting notice for Feb 2025 offering; completes 1-for-25 reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Petros on April 28 of public interest concerns regarding its February 19, 2025 public offering as a new delisting basis under Rule 5810(d).","Company intends to address concerns before a Nasdaq Hearings Panel; delisting actions are stayed pending the hearing.","1-for-25 reverse stock split effective 4:05 pm ET April 30, 2025; split-adjusted trading began May 1, 2025, under same symbol PTPI.","No fractional shares issued; authorized shares remain 7 billion; proportionate adjustments made to options and equity plan.","New CUSIP number is 71678J308; the reverse split does not immediately affect trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160134,"accession_number":"0001104659-25-034283","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["3.01","3.03","5.03","5.02","5.07","9.01"],"status":"ready","headline":"Petros receives Nasdaq equity deficiency delisting notice; shareholders approve massive share increase and reverse split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Petros on Apr 8 it fails $2.5M minimum stockholders' equity requirement, adding to existing bid price deficiency.","All delisting actions stayed pending hearing before Nasdaq Hearings Panel; company intends to address concerns.","At special meeting Apr 10, stockholders approved increasing authorized common shares from 250M to 7B.","Also approved reverse stock split at ratio of 1-for-250 to 1-for-500, at Board's discretion.","Approved increase in incentive plan shares by 1B to 1,002,760,000, and issuance of shares underlying Series Warrants from Feb 2025 offering (approx 1.06B shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160133,"accession_number":"0001104659-25-033391","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Petros Pharmaceuticals terminates Marcum as auditor, engages CBIZ; prior reports include going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company terminated Marcum LLP as auditor on April 5, 2025, and engaged CBIZ CPAs P.C. as new independent auditor for FY 2025.","No disagreements or reportable events except a material weakness in internal controls over financial reporting disclosed in 2024 10-K.","Marcum's reports for FY 2023 and 2024 included an explanatory paragraph about substantial doubt as a going concern.","Marcum provided a letter to SEC dated April 9, 2025, agreeing with the company's statements (Exhibit 16.1 filed)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178450,"accession_number":"0001104659-25-016181","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Petros Pharmaceuticals Prices $9.6 Million Public Offering of Common Stock and Warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Petros Pharmaceuticals entered securities purchase agreement for 13,950,012 units and 26,049,988 pre-funded units at $0.24 and $0.2399 per unit.","Offering closed on February 19, 2025, with gross proceeds of approximately $9.6 million.","Each unit includes one share (or pre-funded warrant), one Series A warrant (0.25 share) and one Series B warrant (1 share) at $0.48 exercise price.","Warrants exercisable only upon stockholder approval; pre-funded warrants immediately exercisable at $0.0001 per share.","Company granted 1,000,000, 300,000, 150,000, 450,000, 150,000, and 150,000 restricted shares to directors Silverman, Bernstein, Walker, Boctor, Arnold, and Weinstein."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178449,"accession_number":"0001104659-25-005980","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["1.01","3.03","5.03","9.01"],"status":"ready","headline":"Petros Pharmaceuticals amends Series A Preferred; maturity extended to Feb 2025, $500k cash covenant added","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended maturity date of Series A Convertible Preferred Stock from prior date to February 15, 2025.","Deferred all unpaid accrued amounts under the Certificate of Designations to February 15, 2025.","Company must maintain at least $500,000 in unrestricted cash from January 15 to February 15, 2025.","Amended restrictive covenant to allow changes in sales strategy for Stendra avanafil and OTC switch platform.","Required holders waived any breach from failure to pay outstanding amounts as of January 23, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195118,"accession_number":"0001104659-24-128984","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["2.04","9.01"],"status":"ready","headline":"Petros subsidiary defaults on $7.25M note; Vivus forecloses on collateral for $2M partial satisfaction","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Metuchen failed to pay installment due Oct 1, 2024; all obligations accelerated.","Outstanding principal $7,246,634.90 plus interest $237,300.35 at default rate of 9%.","Secured party Vivus LLC proposed acceptance of foreclosed collateral in partial satisfaction of $2M obligations.","Metuchen agreed to foreclosure on Dec 13, 2024; remaining obligations continue.","Collateral excludes a Specified License Agreement; no other terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195117,"accession_number":"0001104659-24-121603","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Petros Pharma stockholders OK reverse stock split up to 1:25","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Silverman, Bernstein, Walker elected to one-year terms.","Reverse stock split (range 1:2 to 1:25, Board discretion) approved; For 2,949,518, Against 1,350,781.","Marcum LLP ratified as independent auditor for FY2024 with 3,984,099 for votes.","Advisory say-on-pay proposal passed with 1,433,687 for votes.","Adjournment proposal passed to allow further proxy solicitation if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195116,"accession_number":"0001104659-24-109893","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Petros Pharma reduces President Boctor's base salary to $280K, sets Dec 31 termination","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary cut from $350K to $280K effective Oct 16, 2024.","Employment termination date set to Dec 31, 2024; at-will status continues.","Boctor now permitted to engage in other consulting/employment activities if no conflict.","Amendment approved by Director Josh Silverman."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195115,"accession_number":"0001104659-24-109575","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["1.01","3.03","5.03","9.01"],"status":"ready","headline":"Petros Pharmaceuticals amends Series A Preferred to grant voting rights at $2.25 conversion price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment grants Series A Preferred holders voting rights on as-converted basis at $2.25/share conversion price.","Certificate of Amendment filed with Delaware Secretary of State, effective October 11, 2024.","Required Holders (majority of outstanding preferred) agreed; no additional consideration paid to investors.","Amendment modifies terms from original July 2023 Securities Purchase Agreement; no other changes to transaction documents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195114,"accession_number":"0001104659-24-106322","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two directors resign from Petros Pharmaceuticals board without disagreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Shulman resigned as director effective Oct 1, 2024; no disagreement cited.","Greg Bradley resigned as director effective Oct 2, 2024; no disagreement cited.","No replacements announced; remaining board composition unclear."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211396,"accession_number":"0001104659-24-101333","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Petros Pharmaceuticals sets 2024 annual meeting for Nov 20; shareholder proposals due Sept 29","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting scheduled for November 20, 2024; record date October 14, 2024.","Shareholder proposals under Rule 14a-8 must be received by September 29, 2024.","Director nominations and other business proposals also due September 29, 2024.","Meeting date changed by more than 30 days from 2023 anniversary, triggering new deadlines.","Universal proxy rule compliance notice must be provided by September 29, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248466,"accession_number":"0001104659-24-037906","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Petros enters waiver/amendment with investors covering Dec 2023 equity awards and warrant terms","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Waives breach from Dec 21, 2023 issuance of 348,711 shares/options; deems them Excluded Securities.","Amends Section 4(c) of Warrants clarifying Black Scholes Value rights in Fundamental Transactions.","Waiver and Amendment effective as of December 31, 2023, entered March 21, 2024.","No additional consideration paid to investors; all holders of Preferred Stock and Warrants are party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248465,"accession_number":"0001104659-24-003706","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2024-01-12T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Petros Pharmaceuticals dismisses EisnerAmper as auditor, appoints Marcum; cites material weaknesses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed EisnerAmper as independent auditor on January 8, 2024; engaged Marcum effective immediately.","EisnerAmper's reports for FY2021 and FY2022 contained a going-concern paragraph due to net losses and negative cash flows.","Material weaknesses in internal control identified for FY2021, FY2022, and Q1-Q3 2023: insufficient monitoring, segregation of duties, IT access.","No disagreements with EisnerAmper on accounting principles or audit scope during the period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265970,"accession_number":"0001104659-23-130468","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Petros Pharma 2023 annual meeting: all director nominees elected, auditor ratified, say-on-pay passes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors John Shulman, Joshua Silverman, Bruce Bernstein, Gregory Bradley, Wayne Walker with over 88% of votes cast for each.","Ratified EisnerAmper as independent auditor for FY 2023: 1,181,138 for, 91,884 against, 2,869 abstain.","Advisory say-on-pay approved: 735,195 for, 30,435 against, 4,208 abstain; broker non-votes 506,053.","All proposals passed at December 29, 2023 Annual Meeting; no other matters voted on."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265969,"accession_number":"0001104659-23-130046","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2023-12-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Petros Pharmaceuticals awards 49,645 shares and options to President Boctor, options to VP Arnold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["One-time grant to President & CCO Fady Boctor: 49,645 common shares and options for 109,066 shares at $1.41.","50% of Boctor's options vested on grant; remaining vest based on 2023-2024 strategic goals.","One-time grant to VP Finance & CAO Mitchell Arnold: options for 20,000 shares at $1.41, fully vested.","Grants made under Amended and Restated 2020 Omnibus Incentive Compensation Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265968,"accession_number":"0001104659-23-105624","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Petros Pharmaceuticals amends Series A Preferred Stock redemption and conversion procedures","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Amendment to Series A Convertible Preferred Stock with Delaware Secretary of State on Sept 29, 2023.","Amendment permits additional procedures for payment of redemptions and conversions.","No change to conversion ratio, dividend rate, or liquidation preference was disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283190,"accession_number":"0001104659-23-101208","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2023-09-15T23:59:59+00:00","items":["3.03","5.03","5.02","5.07","9.01"],"status":"ready","headline":"Petros shareholders approved authorized share increase to 250M and incentive plan share increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 150M to 250M via charter amendment filed Sept 14, 2023.","Incentive plan share pool increased by 2.5M shares to 2.76M total, approved by stockholders.","Issuance of shares underlying convertible preferred stock and warrants (over 20% of outstanding) also approved.","Vote results: Share increase 728,964 for, 20,658 against; incentive plan 685,428 for, 64,669 against.","Special meeting held Sept 14, 2023; all four proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283189,"accession_number":"0001104659-23-092020","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2023-08-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Petros Pharmaceuticals lowers stockholder quorum requirement from majority to one-third","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amendment reducing quorum from majority to one-third of outstanding voting shares.","Amendment effective August 15, 2023, applies to all stockholder meetings and class votes.","Change aims to facilitate conducting business at meetings by lowering the attendance threshold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283188,"accession_number":"0001104659-23-080765","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["1.01","3.02","5.03","8.01","9.01"],"status":"ready","headline":"Petros Pharmaceuticals raises $15M via private placement to advance OTC STENDRA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 15,000 Series A Convertible Preferred shares (stated value $1,000 each) and warrants for up to 6,666,668 common shares at $2.25.","Gross proceeds of $15M; cash on hand $8.3M (March 31, 2023); expect funding through end of 2024.","Proceeds to support OTC switch program for STENDRA (erectile dysfunction) including FDA engagements and pivotal Label Comprehension Study.","Placement led by largest existing shareholders; directors/officers holding ~29% of common stock agree to vote for Nasdaq approval.","Closing expected July 17, 2023; Katalyst Securities served as placement agent (8% cash fee + warrants)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340305,"accession_number":"0001104659-22-123235","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2022-11-30T23:59:59+00:00","items":["3.03","5.03","5.07","7.01","9.01"],"status":"ready","headline":"Petros Pharmaceuticals effectuates 1-for-10 reverse stock split effective Nov 30, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split at ratio of 1-for-10 at Nov 29 annual meeting.","Effective 4:05 PM ET Nov 30; shares begin trading on split-adjusted basis Dec 1 under symbol PTPI.","Outstanding shares reduced from 20,708,024 to approx 2,070,803; fractional shares rounded up.","Proportionate adjustments made to equity awards, warrants, and convertible preferred.","CUSIP changes to 71678J209; authorized shares unchanged at 150M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340304,"accession_number":"0001104659-22-118973","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2022-11-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Petros Pharma Q3 net sales negative $1.4M, net loss $13.8M on excessive returns","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales of -$1.4M vs $2.1M YoY; Prescription Medicines segment net sales -$2.1M due to expired product returns.","Gross profit -$1.7M (Q3 2021: $1.8M); SG&A reduced to $2.2M from $3.4M on cost-cutting.","Net loss widened to $13.8M from $1.7M; cash $11.2M vs $13.3M prior quarter.","FDA approved label expansion for STENDRA (avanafil) for ED in men post-radical prostatectomy.","Company shifts primary focus to over-the-counter access for STENDRA, citing improved shelf life."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":5193953.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357575,"accession_number":"0001104659-22-090711","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Petros Pharmaceuticals reports Q2 net sales of $4.2M, first positive adjusted EBITDA of $0.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales of $4.2M, up 68% from $2.5M in Q2 2021; net loss narrowed to $1.8M from $2.1M.","First positive adjusted EBITDA of $0.2M, compared to negative $2.0M in prior-year period.","Prescription Medicines segment (STENDRA) sales up 102% YoY to $3.3M; gross margin stable at 84%.","Cash balance $13.3M as of June 30, 2022, down from $17.7M at March 31, 2022.","Announced positive OTC label comprehension study for STENDRA and pursuit of 505(b)(2) pathway for H-100 for Peyronie's disease."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":6651685.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357574,"accession_number":"0001104659-22-083530","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Petros Pharmaceuticals denies fraudulent acquisition press release; reports to Nasdaq","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["A press release issued July 28, 2022 claiming an acquisition of Petros was fraudulent and not authorized by the company.","Petros confirms it is not a party to any such acquisition and has reported the matter to Nasdaq.","The company urges stakeholders to disregard the false press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376166,"accession_number":"0001104659-22-074363","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2022-06-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Petros Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on June 22, 2022 for bid price <$1.00 over 30 consecutive business days ended June 21, 2022.","Company has 180-day compliance period until December 19, 2022 to regain compliance by closing at $1.00 for 10 consecutive business days.","If not compliant by Dec 19, may qualify for additional 180 days by meeting all other listing standards and effecting reverse stock split if necessary.","No immediate impact on listing; common stock continues trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376165,"accession_number":"0001104659-22-050367","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2022-04-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Petros Pharmaceuticals enters research agreement with Mass General for oxygenation sensor in erectile therapy","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Signed Sponsored Research Agreement and Option Agreement with Wellman Center of Massachusetts General Hospital.","Goal is to evaluate tissue-specific oxygenation sensor to monitor success of Erectile Device Therapy.","Option agreement allows Petros to negotiate an exclusive license of the sensor technology for specific human tissues.","Sensor intended to provide bio-sensor feedback for at-home penile therapy, enhancing existing erectile device therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376164,"accession_number":"0001104659-22-042215","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2022-04-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Petros Pharma reports 2021 net sales $7.8M, net loss down 56% to $9.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $7.8M vs $9.6M in 2020; prescription sales fell to $4.6M due to competitive coupons.","Gross profit up 13% to $6.2M on lower write-offs and fulfillment costs; SG&A flat at $15.6M.","Net loss improved to $9.0M from $20.6M, largely from reduced fair value derivative liability.","Cash at year-end ~$24M; pursuing OTC switch for STENDRA with two self-selection studies launched.","Collaboration with Dr. Drew Pinsky to raise men's health awareness; H100 Peyronie's license expanded."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":2465169.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376163,"accession_number":"0001104659-22-041818","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K/A","filed_at":"2022-04-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Petros Pharmaceuticals board sets annual say-on-pay votes after advisory vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board determined future Say-on-Pay Votes will be held every year, consistent with stockholder preference expressed at 2021 Annual Meeting.","Decision made on March 31, 2022; next frequency re-evaluation scheduled for 2027 Annual Meeting unless earlier.","Amendment solely adds this disclosure; no other changes to Original Form 8-K reporting voting results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394521,"accession_number":"0001104659-22-030657","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2022-03-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Subsidiary President Andrew Gesek resigns; Petros to integrate his role","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Andrew Gesek resigned as President of Timm Medical Technologies effective Feb 28, 2022; no disagreement cited.","Company will not hire a replacement; plans to streamline and integrate operations under current leadership.","Gesek receives $75,000 cash severance (3 months base salary) paid pro rata over three months.","Severance includes 24-month non-compete, non-solicitation, and non-disparagement covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394520,"accession_number":"0001104659-22-006678","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2022-01-24T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Petros Pharmaceuticals signs manufacturing agreement with Thermo Fisher's Patheon for Stendra","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Metuchen (Petros subsidiary) and Patheon (Thermo Fisher) will collaborate on tech transfer and validation to manufacture Stendra at Patheon's Cincinnati facility.","Agreement covers pharmaceutical development and technology transfer services to establish and validate Patheon's ability to supply Stendra.","Commercial sale of product produced during the agreement requires a subsequent commercial manufacturing services agreement.","After successful validation, parties will execute a commercial manufacturing agreement for release of commercially saleable products.","Agreement effective until services completed; each party may terminate under customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394519,"accession_number":"0001104659-22-006487","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2022-01-21T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Petros subsidiary settles VIVUS disputes, issues $10.2M promissory note at 6% through 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Metuchen settles with VIVUS, forgives $9.6M in liabilities and retains ~$7.3M of API inventory.","Issues $10,201,758 promissory note at 6% interest, payable quarterly from Apr 2022 to Jan 2027.","License amended: VIVUS gets co-exclusive rights to Stendra but forbears from exercising unless default.","Metuchen must pay $900k toward note and $1.54M for 2021 purchase order to release inventory.","VIVUS granted right of first refusal on future debt/convertible equity financings until note paid in full."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413138,"accession_number":"0001104659-21-153622","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2021-12-27T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Petros Pharmaceuticals raises $7.5M in registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 2,186,589 shares at $3.43 each to accredited investors, including largest shareholder.","Issued warrants to purchase up to 1,639,942 shares at $3.50, exercisable for five years.","Net proceeds expected ~$6.9M after fees; used for men's health platform expansion and working capital.","Katalyst Securities served as financial advisor; receives $560K fee and 110,000 warrants.","Closing occurred December 27, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413137,"accession_number":"0001104659-21-152914","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2021-12-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders re-elect all five directors and approve 1.52M share increase to incentive plan at 2021 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees (Shulman, Silverman, Bernstein, Bradley, Walker) re-elected with >99% votes cast in favor.","Second Amendment to 2020 Omnibus Incentive Plan approved (5.86M for, 85K against), increasing shares reserved to 2.6M.","EisnerAmper LLP ratified as independent auditor for FY2021 with 9.18M votes for, 36.8K against.","Advisory say-on-pay passed with 5.89M for (98.9% of votes cast); shareholders chose 1-year frequency for future votes.","Voter turnout: 9.23M of total voting power; broker non-votes of ~3.26M on most proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413136,"accession_number":"0001104659-21-145529","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2021-12-01T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Petros Pharmaceuticals raises $10M in registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $10M from sale of 3,333,333 shares at $3.00/share; net proceeds ~$9.3M.","Issues warrants to purchase 2,500,000 shares at $3.50/share, exercisable for 5 years.","Largest shareholder among existing investors; Katalyst Securities acted as financial advisor.","Proceeds to be used for men's health platform expansion and general corporate purposes.","Closing expected on or about December 2, 2021, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413135,"accession_number":"0001104659-21-140632","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2021-11-17T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Petros Pharmaceuticals sets Dec 22, 2021 annual meeting; Nov 27 deadline for shareholder proposals","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting set for December 22, 2021; record date November 18, 2021.","No annual meeting held in 2020; company provides extended deadlines for proposals.","Deadline for Rule 14a-8 shareholder proposals is November 27, 2021 at 5:00 p.m. ET.","Proposals must comply with SEC rules and company bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413134,"accession_number":"0001104659-21-139500","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2021-11-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Petros Pharma Q3 net sales fall 37% to $2.2M; net loss narrows to $1.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $2.2M, down from $3.5M YoY; Prescription Medicines net sales declined 47% due to higher allowances and returns.","Net loss improved to $1.7M vs $3.3M YoY; adjusted EBITDA loss $1.9M.","Record STENDRA prescriptions and tablet sales; total mg sold up 6% sequentially.","Completed enrollment of pivotal label comprehension study for OTC switch of STENDRA; no FDA-approved OTC ED drug exists.","Cash $8.1M at Sep 30; raised $5.3M net in October 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":8678424.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413133,"accession_number":"0001104659-21-126794","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2021-10-15T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Petros Pharmaceuticals raises ~$5.7M in registered direct offering led by largest shareholder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 3,323,616 shares at $1.715 per share; warrants for same number at same price, 5-year term.","Gross proceeds ~$5.7M; net proceeds ~$5.4M after fees; expected close Oct 18, 2021.","Proceeds will fund expansion of men's health platform and general corporate purposes.","Katalyst Securities served as financial advisor; advisory fee and expenses $235,000 plus 130,000 warrants.","Largest shareholder led the offering; warrants issued in private placement, unregistered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}